MEDIROM HEALTHCARE TECHNOLOG (MRM)

US58510H1032 - ADR

1.185  -0.04 (-3.01%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MRM. MRM was compared to 69 industry peers in the Diversified Consumer Services industry. MRM may be in some trouble as it scores bad on both profitability and health. MRM has a expensive valuation and it also scores bad on growth.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRM was profitable.
In the past year MRM has reported a negative cash flow from operations.
In multiple years MRM reported negative net income over the last 5 years.
In the past 5 years MRM reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of MRM (1.68%) is comparable to the rest of the industry.
MRM has a better Return On Equity (54.73%) than 93.94% of its industry peers.
Industry RankSector Rank
ROA 1.68%
ROE 54.73%
ROIC N/A
ROA(3y)-4.44%
ROA(5y)-4.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MRM's Profit Margin of 1.69% is in line compared to the rest of the industry. MRM outperforms 54.55% of its industry peers.
In the last couple of years the Profit Margin of MRM has declined.
MRM has a worse Gross Margin (22.98%) than 84.85% of its industry peers.
In the last couple of years the Gross Margin of MRM has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 1.69%
GM 22.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-2.63%
GM growth 3Y21.41%
GM growth 5Y-3.79%

More info and screens

0

2. Health

2.1 Basic Checks

MRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRM has about the same amout of shares outstanding than it did 1 year ago.
MRM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MRM has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.65, we must say that MRM is in the distress zone and has some risk of bankruptcy.
MRM has a Altman-Z score (0.65) which is in line with its industry peers.
MRM has a Debt/Equity ratio of 6.88. This is a high value indicating a heavy dependency on external financing.
MRM's Debt to Equity ratio of 6.88 is on the low side compared to the rest of the industry. MRM is outperformed by 87.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.88
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC4.98%

2.3 Liquidity

A Current Ratio of 0.49 indicates that MRM may have some problems paying its short term obligations.
With a Current ratio value of 0.49, MRM is not doing good in the industry: 87.88% of the companies in the same industry are doing better.
MRM has a Quick Ratio of 0.49. This is a bad value and indicates that MRM is not financially healthy enough and could expect problems in meeting its short term obligations.
MRM's Quick ratio of 0.45 is on the low side compared to the rest of the industry. MRM is outperformed by 87.88% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.45

More info and screens

2

3. Growth

3.1 Past

MRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.97%.
Measured over the past years, MRM shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.09% on average per year.
Looking at the last year, MRM shows a decrease in Revenue. The Revenue has decreased by -1.81% in the last year.
Measured over the past years, MRM shows a quite strong growth in Revenue. The Revenue has been growing by 14.74% on average per year.
EPS 1Y (TTM)-17.97%
EPS 3YN/A
EPS 5Y10.09%
EPS Q2Q%58.23%
Revenue 1Y (TTM)-1.81%
Revenue growth 3Y26.9%
Revenue growth 5Y14.74%
Sales Q2Q%-5.83%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.75 indicates a rather expensive valuation of MRM.
MRM's Price/Earnings ratio is a bit cheaper when compared to the industry. MRM is cheaper than 66.67% of the companies in the same industry.
When comparing the Price/Earnings ratio of MRM to the average of the S&P500 Index (27.29), we can say MRM is valued slightly cheaper.
Industry RankSector Rank
PE 19.75
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.96
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIROM HEALTHCARE TECHNOLOG

NASDAQ:MRM (12/23/2024, 8:20:16 PM)

1.185

-0.04 (-3.01%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)05-30 2023-05-30
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change52634.6%
Ins Owners40.37%
Ins Owner ChangeN/A
Market Cap9.36M
Analysts0
Price TargetN/A
Short Float %1.36%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 19.75
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 6.96
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.06
EY5.06%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS5.51
BVpS0.17
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)1.96
Profitability
Industry RankSector Rank
ROA 1.68%
ROE 54.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.69%
GM 22.98%
FCFM N/A
ROA(3y)-4.44%
ROA(5y)-4.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-2.63%
GM growth 3Y21.41%
GM growth 5Y-3.79%
F-Score2
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 6.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 365.02%
Cap/Sales 13.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.45
Altman-Z 0.65
F-Score2
WACC4.98%
ROIC/WACCN/A
Cap/Depr(3y)181.87%
Cap/Depr(5y)124.18%
Cap/Sales(3y)6%
Cap/Sales(5y)3.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.97%
EPS 3YN/A
EPS 5Y10.09%
EPS Q2Q%58.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.81%
Revenue growth 3Y26.9%
Revenue growth 5Y14.74%
Sales Q2Q%-5.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-503.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-82.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.87%
OCF growth 3YN/A
OCF growth 5YN/A